Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Biovail Cardizem XL NDA Highlights Nighttime Dose For Cardiac AE Prevention

  • News

Executive Summary

Biovail's NDA for hypertension agent Cardizem XL (diltiazem) highlights nighttime dosing aimed at achieving maximum drug levels between 6 a.m. and noon, when the majority of adverse cardiac events take place.

You may also be interested in...



Biovail Cardizem LA Bedtime/Morning Dosing Flexibility Included In Label

Biovail will launch Cardizem LA on April 2 following FDA's Feb. 6 approval of the "graded-release," once-daily diltiazem for hypertension

Biovail Cardizem LA Bedtime/Morning Dosing Flexibility Included In Label

Biovail will launch Cardizem LA on April 2 following FDA's Feb. 6 approval of the "graded-release," once-daily diltiazem for hypertension

Biovail Vasotec/Cardizem Fixed-Dose Combination Data Expected By July

Biovail expects results from a Phase III trial of several fixed-dose combinations of Vasotec and Cardizem XL in the first half of the year

Table

View full table

Tags:
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS038432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By